FierceBiotech2h
Glucotrack’s 3-year diabetes sensor implant clears initial human safety trial
Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...
FierceBiotech3h
Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy’s first year
Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...
FierceBiotech3h
'Tough but necessary decisions': Frontier Medicines lays off staff to streamline operations
Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...
FierceBiotech19h
Amgen's early-stage obesity asset slapped with FDA hold
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...
FierceBiotech8h
GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
FierceBiotech4h
Qlaris sees double as drug reduces eye pressure in pair of phase 2 trials
Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).
FierceBiotech6h
Novo flunks kidney disease trial, again linking obesity prospect to neuropsychiatric side effects
Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...
FierceBiotech23h
Canadian CRO Innovaderm seeks to grow in rheumatology field with new CEO
Canadian CRO Innovaderm Research is looking to grow with new CEO Jeff Smith leading the way. | Canadian CRO Innovaderm Research is looking to grow with new CEO Jeff Smith leading the way. Smith is ...